Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
33 enrolled 14 charts
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Phase 2 Completed
289 enrolled 34 charts
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Phase NA Completed
23 enrolled 8 charts
VCR
Phase 2 Completed
24 enrolled 11 charts
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Phase 1 Completed
18 enrolled
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Phase 2 Completed
21 enrolled 10 charts
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase 2 Completed
279 enrolled 28 charts
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 1/2 Completed
79 enrolled 19 charts
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
12 enrolled
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Phase 2 Completed
103 enrolled 6 charts
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase 1 Completed
93 enrolled
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
18 enrolled
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Phase 2 Completed
55 enrolled 12 charts
Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
15 enrolled
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
VERTICAL
Phase 2 Completed
73 enrolled 8 charts
PS-341 in Treating Patients With Advanced Cancer
Phase 1 Completed
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Phase 2 Completed
66 enrolled